Abstract:Anaplastic lymphoma kinase (ALK) is an orphan receptor tyrosine kinase (RTK), structurally belonging to the insulin receptor family. The identification of ALK fusion genes NPM-ALK and EML4-ALK in ALCL and NSCLC respectively, and clinical outcomes resulting from aberrant ALK signalling in different human cancers has confirmed the emergence of ALK as a novel and promising ‘personalized’ anticancer drug target. The development of small molecule ALK inhibitors has been accelerated and validated by the recent approval of crizotinib. Unfortunately, similar to other RTK inhibitors, resistance to crizotinib has been reported within a year of starting therapy. Different from the acquired resistance to EGFR inhibitors, the resistance to crizotinib was much more complex and driven by more than twenty secondary mutations, including the gate-keeper L1196M, and the C1156Y near the α-C-helix. In the course of our drug discovery program toward the discovery of novel ALK inhibitors, we took advantage of the 2,4-diarylaminopyrimidine (DAAP) scaffold that has long been recognized as a classical kinase inhibitor motif (TAE684) by introducing an amino acid side chain to the solvent interaction region to bring in additional H-bondings. Therefore, a series of new DAAP analogues (DAAPalogues) were developed and one compound SOMCL-12-81 was identified with high potency against both wild type ALK and L1196M mutations with IC50 values of 2.7 nM and 15.3 nM, respectively. In cellular assay, SOMCL-12-81 displayed an IC50 value of 3.0 nM against the proliferation of EML4-ALK dependent Karpass-299 cells. It was relatively selective (>10-fold) against a panel of in-house 20 RTKs. Dose-dependent tumor growth inhibition was observed in the BF3 rat xenograft model carrying the EML4-ALK fusion gene with daily administration of SOMCL-12-81. The high potency of SOMCL-12-81 both in vitro and in vivo allows it for further investigation. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):B99. Citation Format: Zilan Song, Jing Ai, Zhiqing Liu, Xia Peng, Yi Chen, Jian Ding, Meiyu Geng, Ao Zhang. Discovery of 2,4-diarylaminopyrimidine SOMCL-12-81 as a potent inhibitor targeting both wild and mutant ALK kinases. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr B99.

Dual Potent ALK and ROS1 Inhibitors Combating Drug-Resistant Mutants: Synthesis and Biological Evaluation of Aminopyridine-Containing Diarylaminopyrimidine Derivatives.

Discovery of 2-Aminopyridines Bearing a Pyridone Moiety As Potent ALK Inhibitors to Overcome the Crizotinib-Resistant Mutants

Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1

Discovery of 2,4-Pyrimidinediamine Derivatives As Potent Dual Inhibitors of ALK and HDAC.

Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants

Discovery of 2,4-Diarylaminopyrimidines Bearing a Resorcinol Motif As Novel ALK Inhibitors to Overcome the G1202R Resistant Mutation.

Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib.

Ceritinib (ldk378): A Potent Alternative to Crizotinib for Alk-Rearranged Non-Small-Cell Lung Cancer

Combating Drug-Resistant Mutants of Anaplastic Lymphoma Kinase with Potent and Selective Type-I1/2 Inhibitors by Stabilizing Unique DFG-Shifted Loop Conformation.

Identification and Anti-Tumor Evaluation of 3-Acyl-indol-based 2,4-Diarylaminopyrimidine Analogues As Potent ALK Inhibitors Capable of Overcoming Drug-Resistant Mutants.

Discovery of 2-Aminopyrimidine Derivatives As Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced Herg Inhibitory Activities.

Design, Synthesis and Biological Evaluation N2-(2-alkyoxy-6-aliphatic Aminopyridin-3-yl)-2,4-diaminepyrimidine Derivatives Bearing Acylamino or DBTD ‘head’ As Potential ALK Inhibitors

Design, Synthesis, and Biological Evaluation of Dual Inhibitors of EGFRL858R/T790M/ACK1 to Overcome Osimertinib Resistance in Nonsmall Cell Lung Cancers

Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation

Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors

Design, Synthesis and Pharmacological Evaluation of ALK and Hsp90 Dual Inhibitors Bearing Resorcinol and 2,4-Diaminopyrimidine Motifs.

Synthesis And Evaluation Of Novel 2,4-Diaminopyrimidines Bearing A Sulfoxide Moiety As Anaplastic Lymphoma Kinase (Alk) Inhibition Agents

Discovery of orally bioavailable ALK PROTACs based Ceritinib against ALK positive cancers

Discovery of Potent and Effective Inhibitors Containing Sulfoxide Structures Targeting EML4-ALK Rearrangement and EGFR Mutant Non-Small Cell Lung Cancer

Abstract B99: Discovery of 2,4-Diarylaminopyrimidine SOMCL-12-81 As a Potent Inhibitor Targeting Both Wild and Mutant ALK Kinases.

Discovery of Novel 2,4-Diarylaminopyrimidine Analogues (daapalogues) Showing Potent Inhibitory Activities Against Both Wild-Type and Mutant Alk Kinases